Personalis, Inc. (PSNL)
| Market Cap | 575.73M |
| Revenue (ttm) | 69.65M |
| Net Income (ttm) | -81.27M |
| Shares Out | 104.68M |
| EPS (ttm) | -0.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,065,257 |
| Open | 5.94 |
| Previous Close | 5.96 |
| Day's Range | 5.42 - 5.95 |
| 52-Week Range | 3.62 - 11.50 |
| Beta | 2.21 |
| Analysts | Strong Buy |
| Price Target | 12.20 (+121.82%) |
| Earnings Date | May 7, 2026 |
About PSNL
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.... [Read more]
Financial Performance
In 2025, Personalis's revenue was $69.65 million, a decrease of -17.69% compared to the previous year's $84.61 million. Losses were -$81.27 million, -0.02% less than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for PSNL stock is "Strong Buy." The 12-month stock price target is $12.2, which is an increase of 121.82% from the latest price.
News
Personalis to Announce First Quarter 2026 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2026 financial results o...
Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the successful presentation of clinical data at the American As...
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that an oral podium presentation featuring colorectal cancer da...
Personalis to Participate in the 25th Annual Needham Virtual Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the 25th Annu...
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of P...
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clin...
Personalis Earnings Call Transcript: Q4 2025
Explosive clinical test growth and two Medicare coverage wins drove momentum in 2025, with 2026 guidance targeting $78–$80 million revenue and 43,000–45,000 clinical tests. Margin compression is expected to persist until further reimbursement, but strong cash reserves support aggressive expansion.
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the fourth quarter and ful...
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen 46th An...
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 fina...
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage for the company's NeXT Personal molecular res...
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in npj Precision Oncology highli...
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG 13th Annual...
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the early access launch of Real-Time Variant Tracker, a powerful new option...
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported certain unaudited preliminary financial and operational results ...
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in Clinical Cancer Research, a j...
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of one of the largest and most comprehensive pa...
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Piper Sandler 37...
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage of its ultrasensitive NeXT Personal® test for...
Personalis Earnings Call Transcript: Q3 2025
Q3 saw 4,388 clinical tests (up 26% sequentially, 364% year-over-year) and $14.5M revenue, with strong MRD adoption and three MolDX dossiers under review. Guidance was revised lower due to biopharma timing and reimbursement delays, but cash discipline remains strong.
Personalis Reports Third Quarter 2025 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2025...
Personalis to Announce Third Quarter 2025 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2025 financial results o...
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (L...
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors grant...
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced its collaboration with a leading breast cancer team from Yale C...